Innovative drug stocks plummet! Hang Seng Healthcare ETF (159892) drops nearly 4%, leading the market ETFs downward

2026-02-27 12:42:00

Abstract generation in progress

Hong Kong stocks in the technology and pharmaceutical sectors collectively declined. The Hang Seng Medicine ETF (159892), which focuses on the innovative drug industry chain, closed down nearly 4%, leading the market ETFs. Holdings such as BeiGene, Legend Biotech, WuXi AppTec, and Yingneng Bio experienced significant declines.

Dongwu Securities stated that the implementation of the FDA’s major review policy has become a key industry focus. It officially establishes “one key clinical trial + confirmatory evidence” as the default standard for new drug approval, ending the decades-long doctrine of “two key clinical trials.” This will significantly shorten R&D cycles, reduce development costs, and release major policy dividends for the global innovative drug industry.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.